Connect
← Return to Smoldering Multiple Myeloma and symptoms
Discussion
Smoldering Multiple Myeloma and symptoms
Blood Cancers & Disorders | Last Active: 2 days ago | Replies (20)Comment receiving replies
Dr Sabine Mai, UM Canada Research Chair in genomic instability and nuclear architecture in cancer, published co-authored findings in the American Journal of Hematology.
The groundbreaking study showed that a method developed by Mai and her team can accurately predict the risk that a patient with “smoldering” multiple myeloma will progress to having multiple myeloma.
Replies to "Dr Sabine Mai, UM Canada Research Chair in genomic instability and nuclear architecture in cancer, published..."
I just put this into ChatGPT and this is what i found:
There’s a lot of exciting movement in tracer development for detecting bone marrow and bone tissue neoplasms. Here’s a breakdown of the most promising approaches:
⸻
🎯 Non-FDG PET Tracers
• Choline PET and Methionine PET target membrane and protein synthesis pathways. Early studies suggest they detect more lesions than FDG, though still in research stages .
• Immuno-PET uses radiolabeled antibodies (e.g., daratumumab‑based agents like ⁸⁹Zr‑DFO‑daratumumab). In a first-in-human phase I, this tracer highlighted known myeloma lesions—and newly discovered ones—in a 6-patient trial .
⸻
🧠 Sabine Mai’s Telomere/Nuclear Architecture Profiling
• Dr. Mai and her team at the University of Manitoba developed a 3D telomere profiling assay (“TeloView”) that assesses genomic instability in smoldering multiple myeloma.
• Based on their study of 168 SMM patients, this telomere-based method can stratify individuals by progression risk to active multiple myeloma, enabling more personalized monitoring and early interventions .
• The method was recently published in the American Journal of Hematology, with broad clinical validation from over 3,000 patients across 30+ studies via Telo Genomics .
⸻
💡 Other Imaging & AI Advances
• Advanced AI and radiomic models applied to CT and MRI are being used to predict focal bone lesion development and minimal residual disease (MRD), offering non‑tracer-based early detection angles .
• Hybrid modalities like PET/MRI and low‑dose PET/CT are also being optimized for staging and prognostic risk assessment in smoldering cases .
Connect
Thank you this is helpful. I am bringing this to my appointments this week. And Easy M. A blood test for a much more detailed data set of the individual peptide transformations for the M-spike. They are offering a free lab test and need to collect before treatment and at least a 0.5 mspike. Just learned about them at a support group meeting here in Rhode Island last week. EasyM Clonotypic Peptide Mass Spectrometry (LC-MS/MS) They are in Canada as well.